{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:15:36Z","timestamp":1791609336093,"version":"4.3.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,12]]},"abstract":"<jats:p>Previous studies have shown that proton pump inhibitors (PPIs) are associated with an increased risk of dementia. However, little is known about the relationship between PPIs use and Parkinson\u2019s disease (PD). This study aimed to examine whether PPI use was associated with an increased risk of developing clinically verified PD. This used data from the Taiwan National Health Insurance Research Database for the period between 1999 and 2011, and patients with PPI use were compared with 1 to 1 propensity score-matched controls by age, sex, cohort entry year, and comorbidity. A multivariate analysis was performed using Cox proportional hazards models to estimate the association between PPI use and PD risk. Subgroup analyses according to sex, age, and comorbidities were also conducted. In total, 56,785 PPI users and 56,785 matched controls were enrolled in this study. In the PPI cohort, 366 patients developed PD during a median follow-up of 5.0 years. The incidence rate of PD was 1.48-fold higher in PPI users than in non-PPI users (90.0 vs 133.2 per 100,000 person-years), with an adjusted hazard ratio of 1.76 (95% confidence interval, 1.48\u20132.08). In the subgroup analysis, the adjusted risk of PD in the PPI and non-PPI cohorts increased in the subgroups regardless of age, sex, and comorbidities. The results of this retrospective, nationwide, population-based cohort study in Taiwan indicate that PPI use is associated with the risk of PD development. Further mechanistic studies on the effect of PPI on PD are needed.<\/jats:p>","DOI":"10.1097\/md.0000000000033711","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:18:48Z","timestamp":1683901128000},"page":"e33711","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Proton pump inhibitor use and the risk for Parkinson\u2019s disease: A nationwide population-based study in Taiwan"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7808-7797","authenticated-orcid":false,"given":"Huan-Lin","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Taitung MacKay Memorial Hospital, Taitung, Taiwan"},{"name":"Mackay Medical College, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yi","family":"Lei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Hung","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Taitung MacKay Memorial Hospital, Taitung, Taiwan"},{"name":"Mackay Medical College, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-8210","authenticated-orcid":false,"given":"Chien-Lin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan"},{"name":"Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"S12","article-title":"Diagnosis and the premotor phase of Parkinson disease.","volume":"72","author":"Tolosa","year":"2009","journal-title":"Neurology"},{"key":"R2-20250504","first-page":"61","article-title":"Symptomatology and medical treatment of Parkinson\u2019s disease.","volume":"2","author":"Schwab","year":"1961","journal-title":"Int J Neurol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"842","DOI":"10.5694\/j.1326-5377.1965.tb72277.x","article-title":"The association of gastro-duodenal ulceration and Parkinson\u2019s disease.","volume":"1","author":"Strang","year":"1965","journal-title":"Med J Aust"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jama.281.4.341","article-title":"Parkinson disease in twins: an etiologic study.","volume":"281","author":"Tanner","year":"1999","journal-title":"JAMA"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1590\/S0004-282X1999000300001","article-title":"Genetics, drugs and environmental factors in Parkinson\u2019s disease. A case-control study.","volume":"57","author":"Werneck","year":"1999","journal-title":"Arq Neuropsiquiatr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.1999.tb00654.x","article-title":"Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome.","volume":"99","author":"Charlett","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/ar4177","article-title":"The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.","volume":"15","author":"Scheiman","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents.","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups.","volume":"2013","author":"Gomez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/00365521.2012.763174","article-title":"Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting.","volume":"48","author":"Hreinsson","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCG.0000000000000393","article-title":"The association of drugs with severity and specific causes of acute lower gastrointestinal bleeding: a prospective study.","volume":"50","author":"Hreinsson","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/MOG.0b013e32833ea9d9","article-title":"Adverse effects of proton pump inhibitor drugs: clues and conclusions.","volume":"26","author":"McCarthy","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis.","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease.","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1060028016673859","article-title":"Association between proton pump inhibitors and microscopic colitis.","volume":"51","author":"Law","year":"2017","journal-title":"Ann Pharmacother"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies.","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Ren Fail"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis.","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00406-014-0554-0","article-title":"Risk of dementia in elderly patients with the use of proton pump inhibitors.","volume":"265","author":"Haenisch","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e0171006","DOI":"10.1371\/journal.pone.0171006","article-title":"Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan.","volume":"12","author":"Tai","year":"2017","journal-title":"PLoS One"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \u201ccommon\u201d neurologic disorders?","volume":"68","author":"Hirtz","year":"2007","journal-title":"Neurology"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease.","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(18)30179-0","article-title":"LRP10 genetic variants in familial Parkinson\u2019s disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.","volume":"17","author":"Quadri","year":"2018","journal-title":"Lancet Neurol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease.","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/187152708783885101","article-title":"Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson\u2019s patients?","volume":"7","author":"Qureshi","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ana.22021","article-title":"Levodopa, methylmalonic acid and neuropathy in idiopathic Parkinson\u2019s disease.","volume":"67","author":"Toth","year":"2010","journal-title":"Ann Neurol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s10620-011-1589-y","article-title":"Association between proton pump inhibitor use and anemia: a retrospective cohort study.","volume":"56","author":"Sarzynski","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MJT.0b013e3181f9f6d2","article-title":"Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole.","volume":"19","author":"Ajmera","year":"2012","journal-title":"Am J Ther"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"29651","DOI":"10.1038\/srep29651","article-title":"Newly Diagnosed anemia increases risk of Parkinson\u2019s disease: a population-based cohort study.","volume":"6","author":"Hong","year":"2016","journal-title":"Sci Rep"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/iub.1144","article-title":"Mechanisms of tryptophan and tyrosine hydroxylase.","volume":"65","author":"Roberts","year":"2013","journal-title":"IUBMB Life"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1093\/jn\/127.12.2282","article-title":"In vivo dopamine metabolism is altered in iron-deficient anemic rats.","volume":"127","author":"Nelson","year":"1997","journal-title":"J Nutr"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jns.2011.03.035","article-title":"Dietary intake of metals and risk of Parkinson\u2019s disease: a case-control study in Japan.","volume":"306","author":"Miyake","year":"2011","journal-title":"J Neurol Sci"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cgh.2009.12.022","article-title":"Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.","volume":"8","author":"Lombardo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1523-5378.2005.00331.x","article-title":"Role of chronic infection and infl ammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism.","volume":"10","author":"Dobbs","year":"2005","journal-title":"Helicobacter"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","article-title":"Small intestinal bacterial overgrowth in Parkinson\u2019s disease.","volume":"20","author":"Tan","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1053\/j.gastro.2005.11.046","article-title":"Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics.","volume":"130","author":"Quigley","year":"2006","journal-title":"Gastroenterology"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","article-title":"Colonic inflammation in Parkinson\u2019s disease.","volume":"50","author":"Devos","year":"2013","journal-title":"Neurobiol Dis"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.autneu.2006.02.015","article-title":"Effects of gastrointestinal infl ammation on enteroendocrine cells and enteric neural reflex circuits.","volume":"126\u2013127","author":"Lomax","year":"2006","journal-title":"Auton Neurosci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:27:06Z","timestamp":1746325626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033711","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}